Celebrex, Vioxx and Bextra were similar popular anti inflammatory drugs until late in 2004. Vioxx was recalled over 8 years ago with the Bextra recall soon after. The drug Celebrex is still sold and used by people today but with strong risk warnings.
Class action claims related to all three of these drugs have settled. The deadline for submitting claims for settlement of the class action in Canada for Pfizer’s drugs Celebrex and Bextra was December 22, 2012. We are acting for some claimants for Celebrexa and Bextra, although most of our clients with similar claims relate to the drug Vioxx manufactured by Merck. All 3 of these drugs are Cox-2 inhibitors which are a specific form of non steroidal anti inflammatory drug which is believed to have the effect of increasing the risk of users to have heart attacks or strokes.
We have submitted claims on behalf of our Bextra and Celebrex clients. We now understand that there have been about 200 claims in total which is a surprisingly low number especially considering the widespread popular use of Celebrex. Bextra was a new drug introduced shortly before the Vioxx recall and there were not very many people taking it. We understand that some claims including those submitted several months ago are still being “assessed” and that no claims have been paid to date. Since the deadline has passed for further claims we have received some claim assessments for our clients and for some we must send in additional material. The assessments we have so far on Bextra look good and those clients are pleased.
For the Vioxx claims we now have finalization of the settlement approval which will allow claims to be filed starting April 20, 2013. There are an estimated 1200 Vioxx claims that are to be submitted with our firm representing a substantial number of the people with Vioxx claims. The Vioxx recall received considerable publicity with many Vioxx users being switched to Celebrex after. The Vioxx claims, which have now taken over 8 years without finalization of the settlement, was fought hard by Merck and had a much higher profile than the case related to Celebrex and Bextra. Pfizer has been far more co-operative in dealing with claims and a settlement was reached about a year earlier with more generous terms to the settlement.
The current Bextra Celebrex status is a definite indicator that it may be some time before Vioxx claims are actually paid. We are now thinking we will not see payments on Vioxx until early 2014. We are optimistic that some Bextra and Celebrex claims will be paid soon. Claims can be filed for Vioxx starting in the second half of April 2013 that process will remain open for 120 days until mid August 2013. Payment of Vioxx claims will not take place until after the deadline when all of the claims have been assessed. Payment is then made “pro-rata” based on a division of the total funds available for the settlement.
PLEASE BE AWARE THAT THE DEADLINE FOR SUBMITTING CELEBREX OR BEXTRA CLAIMS PASSED ON DECEMBER 20, 2012
Pfizer’s Cox 2 inhibitor drug Celebrex is similar to Merck’s Vioxx and Pfizer’s more powerful version Bextra. Celebrex remains on the market and Bextra was banned soon after Vioxx in 2004. While Merck’s equivalent drug Vioxx was the most hotly contested and publicized lawsuit for this type of drug which can trigger heart attacks and ischemic strokes, class action lawsuits proceeded quietly including a Canadian Class Action lawsuit covering both Pfizer products. Celebrex statistically appears to have less problems than the other drugs and for that reason it has been allowed to remain in use. Celebrex compensation is limited to those who were prescribed the drug before 2006 when warnings became stronger.
Both the Merck and Pfizer class action lawsuit settlements include a maximum compensation of $100,000 as base compensation plus an amount for the victim’s family members. For the Vioxx settlement, stroke compensation is to a maximum of $5000 while that limit does not apply to the Pfizer class action lawsuit settlement. The case against Pfizer settled sooner and on a more generous basis which includes additional compensation for loss of income and for “consumer costs” which are the costs of the medication purchased by claimants. In the Vioxx settlement there are reductions in compensation based on numerous other risk factors that in most cases will greatly reduce what is paid. For Bextra and Celebrex the level of compensation is mainly determined by the dosage with lower dosage use claimant limited to $25,000 base compensation. The settlement in Vioxx cases is restricted to cardiovascular conditions and only covers heart attack, ischemic stroke and sudden cardiac death. The Pfizer class action lawsuit settlement includes up to $10,000 as a base amount for “other cardiac, renal or vascular event”. That means less people will be excluded from compensation under that settlement than with the Vioxx settlement.
The Vioxx class action lawsuit settlement totaling about $37 million is triple the amount of dollars as the Pfizer settlement, but there are many more claimants for Vioxx. Court approval hearings are complete for the Vioxx settlement and we have received the Judges’ decision on approval of the settlement. The total of the Pfizer settlement is twelve million dollars. The Pfizer settlement has also been given court approval several months ago and we have submitted applications for compensation for individual clients. Those applications are now being processed and we are waiting for compensation decisions. Bextra has been known to cause severe skin reactions including a horrible and rare condition called Stevens Johnson Syndrome (SJS) and it is compensated too. If you believe you or a family member may qualify for compensation for any of these drugs please call our office or email: firstname.lastname@example.org The claim process is best handled with legal assistance which we can provide on a contingency fee basis. That means we do not charge a fee or any expenses until and unless we get you compensation on your claim.
END OF YEAR UPDATE: THE FOLLOWING POST WAS WRITTEN BY MURRAY MISKIN IN EARLY 2012 NOTING THE CHANGES THEN BEING MADE BY THE MISKIN LAW FIRM. THESE CHANGES HAVE BEEN IMPLEMENTED. OUR WHITBY MAIN OFFICE CLOSED AT THE END OF OCTOBER 2012 AND MURRAY MISKIN DOES SEE CLIENTS IN WHITBY ONE DAY A WEEK BY APPOINTMENT. OUR PETERBOROUGH OFFICE IS NOW OPEN REGULAR BUSINESS HOURS. IT IS NOW PAST THE DEADLINE FOR NEW CELEBREX OR BEXTRA CLAIMS AND THE VIOXX SETTLEMENT IS ABOUT TO BE IMPLEMENTED.
Welcome to the new improved adrworks.com website. This is the website for the Murray Miskin Law Offices in Peterborough and Whitby Ontario Canada. Our website was first created in 1997 and you are seeing the new 3rd Generation of the website created on January 29, 2012 with a further major update in September 2012. The Miskin law practice is changing and we are working with associated lawyers to continue to provide services in the areas of real estate, personal injury, insurance claims, civil litigation and business law. Murray Miskin has narrowed his personal focus in the law practice due to new commitments made in the field of Alternative Dispute Resolution and to avoid conflicts of interest in mediating and arbitrating personal injury cases. Miskin Law will continue to handle claims related to mesothelioma and other asbestos disease compensation and dangerous drug claims. We are working to get payment for our clients on the recently settled Vioxx and Bextra (and Celebrex) cases and are accepting new clients who have suffered compensable injury. We are continuing to seek new clients injured by the Bayer birth control pills Yaz and Yasmin. Murray Miskin is still preparing Wills and Power of Attorney for clients and handling estates.
The Miskin Whitby office will close at the end of October 2012 and the website’s local focus has shifted to Peterborough where Murray Miskin will continue to have an office.
Toll Free: 877-428-8000
Ajax ON: 905-428-8000
Peterborough ON: 705-755-7363
Toronto ON: 416-492-0989
Whitby ON: 905-430-8880
Angela: 112 or Press 3
Anna: 118 or Press 2
Murray: 111 or Press 1
Reception: 100 or Press 0
Main Email: email@example.com
Murray Miskin teaches a course in Toronto to train people to be arbitrators. The next course will be the week of June 17,2013. Lawyers taking the course get all the Professional Development credits they require for 2013. Everyone who takes the course receives a Certificate from the ADR Institute of Ontario and is qualified for Arbitrator membership in the Institute. Full details and registration is available from Miskin Law Office and at our website: www.adrworks.ca